Document Detail

Relationship of Na-K-ATPase inhibitors to blood-pressure regulation in continuous ambulatory peritoneal dialysis and hemodialysis.
MedLine Citation:
PMID:  8704112     Owner:  NLM     Status:  MEDLINE    
Inhibitors of sodium-potassium-activated adenosine triphosphatase (Na-K-ATPase) have been implicated in the pathogenesis of hypertension. In the study presented here, an attempt was made to determine whether differences in the plasma levels and the removal rates of high-molecular weight (HMW) and low-molecular weight (LMW) forms of Na-K-ATPase inhibitors might relate to blood-pressure control in hemodialysis (N = six ultrafiltered and N = six non-ultrafiltered) and CAPD (N = six long-term and N = five short-term) patients. The latter group was studied before the initiation of continuous ambulatory peritoneal dialysis (CAPD) and 2 wk after starting the treatment. The mean blood pressure was significantly reduced after dialysis in the nonultrafiltered hemodialysis group and in both CAPD groups. Plasma levels of both HMW and LMW inhibitors were found to be elevated before dialysis in all patients and were modified only slightly after dialysis. Irrespective of whether ultrafiltration was utilized in hemodialysis patients and despite significant losses of both HMW and LMW inhibitors into CAPD effluent. Because CAPD effluent was found to contain vasopressors that were not exclusively Na-K-ATPase inhibitors, losses of these other vasopressors may contribute to improved blood-pressure control in CAPD in contrast to hemodialysis.
E W Weiler; L F Saldanha; F Khalil-Manesh; B A Prins; R E Purdy; H C Gonick
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American Society of Nephrology : JASN     Volume:  7     ISSN:  1046-6673     ISO Abbreviation:  J. Am. Soc. Nephrol.     Publication Date:  1996 Mar 
Date Detail:
Created Date:  1996-09-11     Completed Date:  1996-09-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9013836     Medline TA:  J Am Soc Nephrol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  454-63     Citation Subset:  IM    
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90049, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / physiology*
Chromatography, High Pressure Liquid
Dialysis Solutions / metabolism
Electrophoresis, Polyacrylamide Gel
Enzyme Inhibitors / metabolism*
Kidney Failure, Chronic / metabolism*,  physiopathology,  therapy
Molecular Weight
Peritoneal Dialysis, Continuous Ambulatory*
Renal Dialysis*
Sodium-Potassium-Exchanging ATPase / antagonists & inhibitors*
Vasoconstrictor Agents / metabolism
Reg. No./Substance:
0/Dialysis Solutions; 0/Enzyme Inhibitors; 0/Vasoconstrictor Agents; EC ATPase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Active kallikrein response to changes in sodium-chloride intake in essential hypertensive patients.
Next Document:  Multicenter clinical validation of an on-line monitor of dialysis adequacy.